Antiviral and immunomodulatory effects of Engystol
https://doi.org/10.21518/2079-701X-2019-8-116-120
Abstract
Respiratory tract infections are among the most common diseases. Most upper respiratory tract infections (URTI) are viral in nature. More than 200 types of viruses, including influenza, parainfluenza, respiratory syncytial virus (RSV), rhinovirus (HRV) and adenovirus (AV), may be the cause of URTI; in some cases, other infectious agents are the cause. The most common pathogens are rhinoviruses, which account for more than 50 per cent of the URTI. The article presents data on the efficacy of Engystol®, a complex drug containing low doses of active ingredients and used for prevention and symptomatic treatment of a number of viral diseases.
About the Authors
R. A. Hanferian
Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia;
Federal State Autonomous Educational Institution of Higher Education «Peoples’ Friendship University of Russia»
Russian Federation
Dr. of Sci. (Med), Professor, Professor of the Department of Immunology and Allergology of the Federal State Autonomous Educational Institution of Higher Education «Peoples’ Friendship University of Russia»; Researcher of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Professor of the Department of Immunology and Allergology of the Federal State Autonomous Educational Institution of Higher Education «Peoples’ Friendship University of Russia»; Researcher of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
N. A. Daihes
Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Director of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Director of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
O. V. Karneeva
Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Deputy Director for Science and Education of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Deputy Director for Science and Education of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
T. I. Garashchenko
Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Scientific Secretary of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Scientific Secretary of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
I. A. Kim
Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Head of the Research Department of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
Russian Federation
Dr. of Sci. (Med), Professor, Head of the Research Department of the Federal State Budgetary Institution «Scientific Clinical Center of Otorhinolaryngology» of the Federal Medico-Biological Agency of Russia
References
1. Herzberger G., Weiser M. Homeopathic Treatment of Infections of Various Origins: A Prospective Study. Biomedical Therapy. 1997;14:123–127.
2. Heilmann A. Ein injizierbares Kombinationspräparat (Engystol N) als Prophylaktikum des grippalen Infekts. Biol Med. 1992;21:225–229.
3. Schmiedel V., Klein P. A complex homeopathic preparation for the symptomatic treatment of upper respiratory infections associated with the common cold: An observational study. Explore (NY). 2006;2:109–114.
4. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–84. doi:10.1038/ni.1863.
5. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5:730–7. doi:10.1038/ni1087.
6. Takeda K., Akira S. TLR signaling pathways. Semin Immunol. 2004;16:3–9. doi:10.1016/j. smim.2003.10.003.
7. Loo Y.-M. and Gale M., Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011 May 27;34(5):680–692. doi: 10.1016/j.immuni.2011.05.003
8. Liu Y., Olagnier D. and Lin R. Host and Viral Modulation of RIG-I-Mediated Antiviral Immunity. Front. Immunol. 2017 January 03. https://doi.org/10.3389/fimmu.2016.00662.
9. Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B., Sharma S., et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010;11:997–1004. doi:10.1038/ ni.1932.
10. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375–86. doi:10.1038/nri1604.
11. Wronski S., Dannenmaier J., Schild S., Macke O., Müller L., Burmeister Y., et al. Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by modulating macrophage phagocytic capacity. PLoS ONE. 2018;13(4):e0195822. https://doi. org/10.1371/journal.pone.0195822.
12. Herzberger G., Weiser M. Homeopathic Treatment of Infections of Various Origins: A Prospective Study. Biomedical Therapy. 1997;14:123–127.
13. Schmiedel V., Klein P. A complex homeopathic preparation for the symptomatic treatment of upper respiratory infections associated with the common cold: An observational study. Explore (NY). 2006;2:109–114.
14. Wagner H., Jurcic K. Immunological studies of plant-extract combinations - invitro and invivo studies on the stimulation of phagocytosis. Arzneimittel-Forschung/Drug research. 1991;41(2):1072–1076.
15. Enbergs H. Effects of the homeopathic preparation Engystol on interferon-gamma production by human T-lymphocytes. Immunol Invest. 2006;35:19–27. doi: 10.1080/08820130500496753.
16. Fimiani V., Cavallaro A., Ainis O., Bottari C. Immunomodulatory effect of the homoeopathic drug Engystol-N on some activities of isolated human leukocytes and in whole blood. Immunopharmacol. Immunotoxicol. 2000;22:103–115. doi: 10.3109/08923970009016409.
17. Matusiewicz R. The effect of a homeopathic preparation on the clinical condition of patients with corticosteroid-dependent bronchial asthma. Biomed Ther. 1997;15:70–74.
18. Siewierrska K, Denys A. Efficacy of preoperative immunoprophylaxis in patients with neoplastic deseases. I. Phagocyte activity and bactericidal properties of peripheral blood granulocytes. Int Rev Allergol Clin Immunol. 1999;5:39–45.
19. Siewierrska K., Denys A. Efficacy of preoperative immunoprophylaxis in patients with neoplastic deseases. II. Estimation of antihaemagglutinin and antineuraminidase antibody titre or influenza viruses A and B. Int Rev Allergol Clin Immunol. 1999;5:46–50.
Review
For citations:
Hanferian RA, Daihes NA, Karneeva OV, Garashchenko TI, Kim IA. Antiviral and immunomodulatory effects of Engystol. Meditsinskiy sovet = Medical Council. 2019;(8):116-120. (In Russ.) https://doi.org/10.21518/2079-701X-2019-8-116-120
Views:
2323
Email this article 